In this section
@article{Daws:2021:rs.3.rs-513323/v1,
author = {Daws, R and Timmerman, C and Giribaldi, B and Sexton, J and Wall, M and Erritzoe, D and Roseman, L and Nutt, D and Carhart-Harris, R},
doi = {rs.3.rs-513323/v1},
title = {Decreased brain modularity after psilocybin therapy for depression.},
url = {http://dx.doi.org/10.21203/rs.3.rs-513323/v1},
year = {2021}
}
TY - JOUR
AB - <title>Abstract</title> <p><bold>Importance </bold>Psilocybin therapy shows antidepressant potential; our data link its antidepressant effects to decreased brain network modularity post-treatment. <bold>Objective </bold>To assess the sub-acute impact of psilocybin on brain activity in patients with depression. <bold>Design </bold>Pre vs post-treatment resting-state functional MRI (fMRI) was recorded in two trials: 1) Open-label treatment-resistant depression (TRD) trial with baseline vs 1 day post-treatment fMRI (April-2015 to April-2016); 2) Two-arm double-blind RCT in major depressive disorder (MDD), fMRI baseline vs 3 week after psilocybin-therapy or 6 weeks of daily escitalopram (January-2019 to March-2020). <bold>Setting </bold>Study visits occurred at the NIHR Imperial Clinical Research Facility.<bold>Participants </bold>Adult male and female patients with TRD or MDD. <bold>Intervention(s) (for clinical trials) or Exposure(s) (for observational studies)</bold>Study 1: Two oral doses of psilocybin (10mg and 25mg, fixed order, 7 days apart). fMRI was recorded at baseline and one day after the 25mg dose. Study 2: either: 2 x 25mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily placebo (‘psilocybin-arm’), or 2 x 1mg oral psilocybin, 3 weeks apart, plus 6 weeks of daily escitalopram [10-20mg] (‘escitalopram-arm’). fMRI was recorded at baseline and 3 weeks after the 2nd psilocybin dose, which was the final day of the 6-week daily capsule ingestion. <bold>Main Outcome(s) and Measure(s) </bold>Beck Depression Inventory and fMRI network modularity. <bold> </bold><bold>Results </bold>Study 1: In 16 adults (mean age [SD], 42.8 [10.1] years, 4 [25%] female), psilocybin therapy<underline> </underline>was associated with markedly decreased BDI scores at 1 week (mean difference, -21; 95% CI=[-27.3, -
AU - Daws,R
AU - Timmerman,C
AU - Giribaldi,B
AU - Sexton,J
AU - Wall,M
AU - Erritzoe,D
AU - Roseman,L
AU - Nutt,D
AU - Carhart-Harris,R
DO - rs.3.rs-513323/v1
PY - 2021///
TI - Decreased brain modularity after psilocybin therapy for depression.
UR - http://dx.doi.org/10.21203/rs.3.rs-513323/v1
UR - https://doi.org/10.21203/rs.3.rs-513323/v1
ER -
